Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.13

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $32.13.

A number of equities research analysts have recently commented on FDMT shares. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, February 10th. Royal Bank of Canada reduced their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating for the company in a report on Thursday, November 14th. Leerink Partners reduced their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating for the company in a report on Monday, January 13th. BMO Capital Markets lowered 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $40.00 to $15.00 in a report on Monday, January 13th. Finally, Bank of America reduced their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, December 18th.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FDMT. nVerses Capital LLC bought a new position in 4D Molecular Therapeutics during the third quarter valued at about $40,000. Assenagon Asset Management S.A. increased its stake in 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company's stock valued at $16,684,000 after acquiring an additional 1,087,147 shares during the period. Values First Advisors Inc. bought a new position in 4D Molecular Therapeutics during the third quarter valued at about $57,000. Novo Holdings A S increased its stake in 4D Molecular Therapeutics by 7.1% during the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company's stock valued at $16,215,000 after acquiring an additional 100,000 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in 4D Molecular Therapeutics by 64.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock valued at $108,000 after acquiring an additional 3,922 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Down 0.6 %

NASDAQ FDMT traded down $0.03 on Thursday, reaching $4.64. 563,286 shares of the stock traded hands, compared to its average volume of 928,929. The firm's fifty day simple moving average is $5.38 and its 200 day simple moving average is $9.00. The company has a market cap of $214.51 million, a price-to-earnings ratio of -1.63 and a beta of 2.81. 4D Molecular Therapeutics has a 12 month low of $4.41 and a 12 month high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.